Cervical Cancer Screening Update, Dr. Lindsey Eastman | Evening Rounds: Ambulatory Lecture Series

Cervical Cancer Screening Update, Dr. Lindsey Eastman | Evening Rounds: Ambulatory Lecture Series

Title history
  • Cervical Cancer Screening Update, Dr. Lindsey Eastman | Evening Rounds: Ambulatory Lecture Series — observed on 20261025-1519 UTC (YouTube)

by Dr. Lindsey Eastman · View the channel on PSI

Life & Natural Systems Medicine & Health MBNPublic health and preventive medicineMBNCMedical screening
🎙 Dr. Lindsey Eastman 👥 426 📅 October 14, 2026 ⏱ 24 min 👁 53 📄 expert opinion 🧭 2026-10-25
Available in: English (current) Français

Keywords

cervical cancer screeningHPVprimary HPV testself-collectionACOG guidelines

Summary

Dr. Lindsey Eastman, an assistant professor in the Department of Obstetrics and Gynecology at UChicago Medicine, presents an update on cervical cancer screening guidelines implemented at the University of Chicago. She begins by defining HPV, noting that about 85% of sexually active individuals will acquire it, with 90% resolving spontaneously within two years. Persistent infection, especially in immunocompromised patients or tobacco users, raises cancer risk. HPV is linked to 90% of cervical and anal cancers, 70% of vaginal and vulvar cancers, 60% of penile cancers, and 60-70% of oropharyngeal cancers. The evolution of screening recommendations is traced: primary HPV testing was endorsed by USPSTF in 2018, American Cancer Society in 2020, and ACOG in 2021. New ACOG guidelines (2026) recommend initiating screening at age 21, with cytology every 3 years for ages 21-29, and primary HPV testing every 5 years (provider-collected) or every 3 years (self-collected) for ages 30 and over. Screening can stop at 65 after adequate negative results. Dr. Eastman explains the rationale for primary HPV testing: higher sensitivity for detecting high-risk lesions, better predictive value for future risk, and fewer unnecessary colposcopies compared to co-testing. The session also covers patient self-collection of HPV samples, eligibility criteria (routine screening, no immunosuppression, no vaginal bleeding or products within 48h), and the workflow: self-collected positive results require a follow-up provider visit for cytology. High-risk populations (e.g., HIV, transplant, inflammatory bowel disease on immunosuppressants) have more intensive screening: start within one year of sexual activity, cytology annually until 3 normal then every 3 years for ages 21-29, and co-testing every 3 years for ages 30+. The presentation concludes with the role of nurses and medical assistants in supporting self-collection and patient education.

281 words

Critical Evaluation

Value of the Information & Strength of the Argument

The lecture provides clear, evidence-based justification for the shift to primary HPV testing. Dr. Eastman presents comparative data showing that a negative HPV test confers a 10-year protection rate against CIN3+, which is superior to cytology alone (3-year protection). She explains why co-testing leads to more colposcopies without increasing cancer detection, thus reducing unnecessary procedures. The argumentation is well-structured, with logical progression from HPV biology to clinical application. Practical details such as self-collection technique and eligibility criteria enhance the practical value for healthcare staff. The speaker’s reliance on authoritative guidelines (ACOG, USPSTF, ACS) strengthens the reasoning. However, the lecture is essentially a guideline review rather than an original study, so the novelty is limited to institutional implementation.

Scientific Rigor, Source Quality, Title Accuracy

The content is rigorous from a scientific standpoint: it references specific societies (ACOG, USPSTF, American Cancer Society) and notes the timeline of their endorsements. No primary research studies are cited by name, but the speaker discusses evidence about sensitivity and predictive values. The title exactly matches the topic, and the presentation is coherent. No comments were provided for analysis.

191 words

Title / Content Match

The title accurately reflects the content: a lecture on updated cervical cancer screening guidelines.

Quality & Reliability

8/10

The presentation is delivered by a faculty clinician at a major academic medical center, with explicit reference to national guidelines from ACOG, USPSTF, and ACS. No financial disclosures or conflicts of interest are declared. The content is technically accurate and aligns with current medical standards, though it reflects institutional implementation rather than original research.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

  • ACOG Cervical Cancer Screening Guidelines (2026) — Mentioned as the primary source for updated screening intervals and methods
  • US Preventive Services Task Force (2018 recommendation) — Cited as first major body endorsing primary HPV screening
  • American Cancer Society (2020 recommendation) — Mentioned as subsequent adoption of primary HPV screening

Concurring Sources

  • ACOG Practice Bulletin on Cervical Cancer Screening — Guidelines referenced align with the video's content.
  • USPSTF Cervical Cancer Screening Recommendation — USPSTF endorsement supports the primary HPV screening approach discussed.

Contribution & Novelties

The lecture highlights recent shifts in cervical cancer screening, particularly the adoption of primary HPV testing and patient self-collection. It provides a practical overview for clinical staff, emphasizing the evidence base for abandoning co-testing in average-risk patients. The institutional protocol for self-collection is clearly outlined.

Pour aller plus loin :

  • HPV and cancer - WHO — Overview of HPV-related cancers and prevention.
  • Cervical cancer screening - NCI — Official U.S. National Cancer Institute resource on screening methods.
  • Human papillomavirus vaccination - CDC — Context on HPV prevention alongside screening.
  • Primary HPV testing self-collection: concept described in the lecture, no direct URL provided in the video.

105 words

Radar Profile

The profile shows strong performance in information quantity and reliability, reflecting comprehensive coverage of guidelines and evidence. Technical depth is moderate, suitable for an interprofessional audience. The overall quality is high, with a well-balanced presentation.

Reliability 8/10